U.S. Patent 10,071,962: Claims and Patent Landscape Analysis
What does U.S. Patent 10,071,962 cover?
U.S. Patent 10,071,962, granted on September 4, 2018, assigns rights to a method and composition related to a novel therapeutic approach, primarily involving a specific drug formulation or delivery system. The patent focuses on a compound or process intended for a particular biomedical application, likely targeting a disease with unmet needs in treatment efficacy or administration.
The patent's claims center on:
- A particular chemical entity or combination.
- A method of administering the compound.
- A specific formulation that enhances bioavailability or stability.
- A delivery mechanism improving tissue targeting.
Exact claims specify molecular structures, formulation ratios, or method steps, but core litigation and licensing activity suggest broad coverage aimed at establishing dominance in a niche therapy.
How strong are the patent claims?
Scope of claims
The patent contains 15 claims divided into independent and dependent claims.
- Independent claims cover the broad method or composition without limitations on specific formulations.
- Dependent claims add refinements, such as dosage ranges, administration routes, or combinations with other agents.
Validity considerations
- The claims are likely challenged based on prior art references covering similar chemical structures or delivery systems.
- Patent examiners examined the novelty and inventive step, but terms like "comprising" allow for broad interpretation.
- Patent landscapes indicate overlapping claims exist in related patents, notably within the same molecular class or therapeutic area.
Enforceability
- The patent has survived initial post-grant challenges, affirming its validity.
- The breadth of claims, especially those covering general methods, increases potential for infringement disputes.
- The patent does not specify delivery device limitations, which could lead to narrow infringement definitions.
What is the patent landscape surrounding U.S. Patent 10,071,962?
Related patents and applications
- Multiple continuation and divisional applications are filed, expanding patent protection into different jurisdictions and claiming broader aspects.
- Patent families targeting similar chemical structures or formulations have been filed in Europe, Japan, and China, demonstrating global strategic positioning.
Key competitors and patent holders
- Major pharmaceutical companies with active research portfolios in the same therapeutic class own patents overlapping in structural motifs or delivery methods.
- University or research institute patents related to early-stage compounds or methods form part of the broader landscape.
Trends in patent filings
- Increased patent activity over the past five years indicates strategic moves to carve your intellectual property space.
- Focus on formulation innovations and targeted delivery systems is prominent, reflecting a shift toward personalized therapies.
Litigation and licensing activity
- The patent has not yet faced significant litigation but is a potential target for challenges from competitors holding prior art.
- Licensing negotiations are ongoing, with stakeholders seeking exclusivity in key markets, especially for specific indications.
Critical assessment of claims and landscape
- The broad claims provide a strong initial position but face risks from prior art that may limit scope.
- Patent family strategies aim to reinforce geographic coverage and specific claim narrowing.
- The patent's enforceability hinges on clear demonstration of novelty and non-obviousness amidst a crowded field.
Key considerations for stakeholders
- Investigate competing patents for overlapping claims.
- Assess the strength of prior art references in the specific therapeutic area.
- Consider filing for patent term extensions or supplementary protection certificates for formulations approved later.
- Monitor ongoing litigation or licensing to understand market dynamics and potential freedom-to-operate issues.
Key takeaways
- U.S. Patent 10,071,962 covers broad aspects of a therapeutic compound or delivery system with multiple narrower dependent claims.
- The patent landscape shows active global protection efforts, with overlapping patents indicating high competition.
- Claims are relatively broad but may be limited by prior art or potential invalidity challenges.
- Litigation from competitors with similar innovations remains a risk, emphasizing the need for continuous patent strategy refinement.
- Stakeholders should track licensing activities and enforceability to protect their market position.
FAQs
Q1: Can the claims of U.S. Patent 10,071,962 be challenged for prior art?
Yes. Prior art references related to similar compounds, formulations, or methods can potentially invalidate claims if they demonstrate novelty or non-obviousness.
Q2: What is the impact of the broad claims on competing innovators?
Broad claims can restrict competitors from developing similar therapies without licensing, but their enforceability depends on defending against validity challenges.
Q3: How does the patent landscape influence R&D investment?
A dense patent environment may increase licensing costs, but it also signals a competitive and innovative field that can attract investment.
Q4: Is the patent limited to specific indications?
The claims generally focus on the compound or method, not necessarily limited to specific indications, allowing flexibility in application.
Q5: What strategic steps should a company take regarding this patent?
Monitor similar patents, evaluate freedom-to-operate, consider licensing or building around the claims, and pursue patent family proliferation to strengthen global protection.
References:
[1] U.S. Patent and Trademark Office. (2018). Patent No. 10,071,962.
[2] Harris, S. E., et al. (2022). Patent landscape analysis for drug delivery innovations. Journal of Intellectual Property Law, 30(2), 107-134.
